Minneapolis, Minnesota -- Medical device technology company CVRx has secured $46.5 million in new equity venture capital financing, according to an SEC regulatory filing.
CVRx has developed an implantable medical device called the Barostim neo.
The device aids in the treatment of high blood pressure and heart failure.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of 17 investors participated in the offering.
CVRx is still seeking $38.5 million in equity investment, according to the filing.